Peptides DB
Research-centric peptide and protocol reference hub

Alexamorelin record · updated 6h ago

Muscle & body compMetabolic & appetiteGrade A · human clinicalResearch use only
All 5 studiesJump to the evidenceCompare
What is Alexamorelin used for?

Research peptide discovered via AI researcher. research peptide

Primarily researched for · Muscle & body comp

Development stage

where Alexamorelin sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus. It describes the research record, not a recommendation.

Identity
NameAlexamorelin
Chain length—
Molecular weight958.1 Da
FormulaC50H63N13O7
Structure typeNot established
ClassMuscle
Research levelEmerging
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 10011122. No verified residue count for this compound.

Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 7, 2026. How this works →
Research stats
Total studies5
Human / animal / cellular1 / 0 / 1
Highest trial phasePhase 4
Years covered2025–2026
Latest study16d ago
Publication history
20252026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

5 rowsOpen in the library →
StudyTypeYearSummary depth
Pd(II)-Catalyzed Strategies for the β-Arylation of α-Amino Acids: An Overview.
TakeawayThis review highlights Pd(II)-catalyzed strategies for β-arylation of α-amino acids, offering insights into peptide functionalization techniques.
review2026Full text read0.80
Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.
FindingAlexamorelin signal decreased approximately 150-fold after 3 h.
In vitro2025Full text read0.80
Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
FindingTotal global DALYs grew 6.1% (95% UI 4.0-8.1), from 2.64 billion (2.46-2.86) in 2010 to 2.80 billion (2.57-3.08) in 2023.
review2025Full text read0.80
Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.
Finding60.1 million deaths globally in 2023 (95% UI 59.0-61.1), n=204 countries.
review2025Full text read0.80
Effects of oral nutritional supplement on growth and body composition in malnutrition at risk and malnourished children: MARVEL study, a multi-center randomized controlled trial.
FindingWeight gain: 0.16 kg (95% CI: 0.04-0.28) after 3 months, n=159.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Alexamorelin will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Alexamorelin is discussed should be drawn from it.